《大行》瑞銀微升中移動(00941.HK)目標價至102元 評級「買入」
瑞銀髮表研究報告,在宏觀經濟逆風下,中移動(00941.HK)次季服務收入按年升0.1%至2,450億元人民幣,EBITDA按年升1%至1,050億元人民幣,低於該行及市場預期介乎1%至2%。
該行表示,管理層維持對全年收入呈穩定增長及純利增長利好等指引,並目標在未來兩至三年時間維持良好增長。該行表示,將2025年至2028年收入預測下調2%至5%,即使宏觀經濟逆風,仍將2025年至2028年純利預測上調0%至2%,反映盈利能力轉佳。
該行將其目標價由101元上調至102元,維持其評級爲「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.